FibroBiologics
FBLGFibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based cell therapies for chronic diseases.
Earnings
Next report
Oct 30, 2026 (in 2 months)Competitors
By market cap
Profile
FibroBiologics is a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based cell therapies for chronic diseases. The company leverages the regenerative and immunomodulatory properties of fibroblasts to address unmet medical needs in wound healing, multiple sclerosis, and degenerative disc disease. Their core value proposition lies in the superior scalability, faster culture time, and enhanced cytokine production of fibroblasts compared to traditional stem cell therapies.
A clinical-stage innovator utilizing a proprietary fibroblast technology platform to compete against established stem cell and monoclonal antibody therapies.
FAQ
- What is FibroBiologics's market cap?
- FibroBiologics (FBLG) has a market capitalization of $9.4M and trades on NASDAQ.
- Who are FibroBiologics's competitors?
- FibroBiologics's key competitors include Biogen, Inc., Johnson & Johnson, Amgen Inc., and others. These companies compete in similar markets and product categories.
- Who does FibroBiologics partner with?
- FibroBiologics's notable partners include SpinalCyte LLC.
- Where is FibroBiologics headquartered?
- FibroBiologics is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2024.